Overview
- The Brain Health Accelerator is a new unit inside the Allen Institute that has about 60 staff now and plans to grow to roughly 200 people, supported by a $400 million funding package that runs over 14 years.
- Funding includes $200 million from the Fund for Science and Technology, plus $100 million from the Bezos family and $100 million from a group including Amazon Web Services, the NIH, and EverythingALS.
- The initiative shifts the institute’s work from descriptive brain mapping toward therapies that target specific cell types and circuits by using genetic regulatory elements found in single-cell genomic maps.
- Researchers will combine very large public datasets with foundation-model–style AI to find cell-type patterns, model disease progression, and guide design of gene-based treatments.
- The accelerator is recruiting academic, industry, and patient-group partners and cites ALS as a promising early target, but its five-year trial goal depends on further partner funding, regulatory steps, and successful translation of maps into safe therapies.